GIP and heart failure: The use of GLP‐1 and GLP‐1/GIP RAs was associated with a significantly reduced risk of the composite endpoint of cardiovascular death or worsening heart failure events compared to the control group [RR: 0.73; 95% CI: 0.57 to 0.93, (p = 0.011) Figure 1A].